Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 111

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 111
---
 live attenuated vaccines are measles-mumps-rubella vaccine and rotavirus vaccine; inactivated vaccines:
hepatitis A and rabies; and protein vaccines: hepatitis B and acellular pertussis. Viral vector and nucleic acid (mRNA and DNA) vaccines
are more novel platforms. The only viral vector vaccine licensed for human use is the Ebola vaccine by Merck.

The success of the vaccines from Pfizer-BioNTech
(BNT162b2, also known as Comirnaty®) and Moderna (mRNA-1273, also known as Spikevax®) in combatting Coronavirus has demonstrated
the value and rapid translational potential of lipid nanoparticles.

The Coronavirus pandemic introduced many millions
of people to mRNA vaccines, saving many lives. These vaccines consist of two main components:

| - | An mRNA molecule, a fragile single                                                               
 strand polymer of nucleic acid that instructs the host cells to produce predetermined protein(s) |

| - | A lipid nanoparticles (LNPs) coating                                   
 that enables an efficient delivery of nucleic acids into living cells. |

<div align='center'>71</div>

Upon injection these vaccines into the muscle,
the mRNA in the vaccine is taken up by muscle cells and muscle immune cells that start producing the desired protein and displaying it
to specialized immune cells. Despite of wide vaccination with the newly introduced mRNA vaccines, since 2020, the rapid evolution and
spread of new Covid variants have caused severe illnesses and national lockdowns, proving to the world how critical it is to prepare for
future potential pandemics.

Mutations of other dangerous viruses that are
easily transferred from animals to humans, such as bird flu, can erupt at any moment, bringing the global healthcare system to the brink
of collapse, as well as triggering a social and economic crisis similar to what occurred during Covid. New mutations of known deadly viral
diseases, such as Ebola, can pose a rapid and aggressive threat to the entire world.

Novel Approach: LPLT by LipoVation

Our team has been focusing on the development
of Liposomal Protein-Loaded Technology (LPLT), a novel immunization platform that we are evaluating for potential use in developing vaccines
against a variety of viral diseases, including Coronavirus, West Nile Virus, Zika, HIV and others. The platform incorporates a proprietary
lipid and a CCS-based delivery system designed to protect virus-specific antigens and support their delivery. This approach may enable
coverage of a broader